Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.
Latest from Cancer Currents
06/27/2023
In a large clinical trial, vorasidenib slowed the growth of low-grade gliomas that had mutations in the IDH1 or IDH2 genes. Vorasidenib is the first targeted drug developed specifically to treat brain tumors.
Read the Story

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Bookmark and Share